GSK1016790A
CAS No. 942206-85-1
GSK1016790A ( GSK1016790A; GSK-1016790A; GSK 1016790A. )
Catalog No. M19275 CAS No. 942206-85-1
GSK1016790A (GSK101) is a novel, potent activator of TRPV4 (transient receptor potential vanilloid 4) with EC50 of 34 nM in choroid plexus epithelial cells.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 37 | In Stock |
|
5MG | 59 | In Stock |
|
10MG | 104 | In Stock |
|
25MG | 228 | In Stock |
|
50MG | 345 | In Stock |
|
100MG | 512 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK1016790A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK1016790A (GSK101) is a novel, potent activator of TRPV4 (transient receptor potential vanilloid 4) with EC50 of 34 nM in choroid plexus epithelial cells.
-
DescriptionGSK1016790A is a TRPV4 agonist that elicits calcium influx in HEK cells expressing mouse or human TRPV4 (EC50s = 18 and 2.1 nM, respectively).
-
SynonymsGSK1016790A; GSK-1016790A; GSK 1016790A.
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorhTRPV4; mTRPV4
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number942206-85-1
-
Formula Weight655.61
-
Molecular FormulaC28H32Cl2N4O6S2
-
Purity98%
-
SolubilityDMSO : ≥ 33 mg/mL; 50.33 mM
-
SMILESCC(C)C[C@H](NC(=O)C1=CC2=C(S1)C=CC=C2)C(=O)N1CCN(CC1)C(=O)[C@H](CO)NS(=O)(=O)C1=C(Cl)C=C(Cl)C=C1
-
Chemical NameN-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Palosuran hydrochlor...
Palosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
-
DS-7423
DS-7423 is a novel potent, small-molecule dual inhibitor of PI3K/mTOR.
-
BYL-719
Alpelisib (BYL-719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.